Asphalion
Asphalion is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
Patient-Centered Study of Trastuzumab Deruxtecan (T-DXd) in First-Line HER2-Positive Metastatic Breast Cancer with Proactive Toxicity Management Reflecting Real-World Clinical Practice / TOP-REAL Trial
Sponsor Solti Group
- Start (EU)
- Latest update
- Estimated end
- Not reported
A multicenter, open-label, non-randomized Phase 1/2 study to assess safety, tolerability, and imaging characteristics of [68Ga]Ga-DPI-4452 and to assess safety, tolerability, and efficacy of [177Lu]Lu-DPI-4452 in patients with unresectable locally advanced or metastatic solid tumors
Sponsor ITM Oncologics GmbH
- Start (EU)
- Latest update
- Estimated end
Phase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419/ANV600) vs High dose IL2 after Tumor Infiltrating Lymphocytes (TIL) Therapy in patients with melanoma, NSCLC and cervical cancer. The PragmaTIL
Sponsor Vall D Hebron Institute Of Oncology
- Start (EU)
- Latest update
- Estimated end
A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor‑positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin
Sponsor ITM Solucin GmbH
- Start (EU)
- Latest update
- Estimated end
A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).
Sponsor ITM Solucin GmbH
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Asphalion?
The 2026-10-09 snapshot links Asphalion to 5 distinct CTIS trials. Recorded services include Safety reporting & pharmacovigilance, other PV-related activities, Regulatory services. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Asphalion?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Endocrinology, Gastroenterology, Musculoskeletal. Recorded phases include Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Asphalion conducted?
The linked trials record locations in 10 countries, including Spain, France, Germany, Netherlands, Belgium. These are trial locations, not confirmed office locations or countries where Asphalion delivered services.
What can this page tell me about Asphalion's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Asphalion. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Asphalion S.L.